Open AccessBeta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study
Author(s) -
Eiichiro Kanda,
Daniel Muenz,
Brian Bieber,
Aleix Cases,
Francesco Locatelli,
Friedrich K. Port,
Roberto Pécoits-Filho,
Bruce M. Robinson,
Jeffrey Perl
Publication year - 2020
Publication title -
clinical kidney journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 40
eISSN - 2048-8513
pISSN - 2048-8505
DOI - 10.1093/ckj/sfaa155
Subject(s) - hemodialysis , medicine , beta 2 microglobulin , hazard ratio , dialysis , poisson regression , confidence interval , proportional hazards model , dialysis adequacy , population , environmental health
Beta-2 microglobulin (β2M) accumulates in hemodialysis (HD) patients, but its consequences are controversial, particularly in the current era of high-flux dialyzers. High-flux HD treatment improves β2M removal, yet β2M and other middle molecules may still contribute to adverse events. We investigated patient factors associated with serum β2M, evaluated trends in β2M levels and in hospitalizations due to dialysis-related amyloidosis (DRA), and estimated the effect of β2M on mortality.